Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2032

The global anticoagulants market size was valued at USD 30.7 billion in 2022 and is predicted to be worth USD 56.6 billion by 2032, with a CAGR of 6.2% from 2023 to 2032. 

Key Pointers:

• The atrial fibrillation & heart attack segment dominated the global market in terms of share in 2022.
• The oral segment accounted for the largest share of the global anticoagulants market in 2022.
• The hospital pharmacies segment dominated the global market in 2022. 
• North America accounted for major share of the market in 2022.
• The market in Asia Pacific is projected to advance at a high CAGR from 2023 to 2032. 

Medicines called anticoagulants stop the blood from clotting. Blood thinners are also referred to as anticoagulants. These medicines are used in order to treat and prevent blood clots that could form in blood vessels. An artery or a vein could be obstructed by blood clots. A blocked artery prevents oxygen and blood from reaching a specific area of the body such as heart, brain, or lungs. Oral anticoagulants and injectable anticoagulants are the two major forms of anticoagulants. The coagulation pathway in the blood is different for each type. Anticoagulants can be used to treat blood clots or lower the risk in situations where they are more likely to occur. People with atrial fibrillation, deep vein thrombosis, hip or knee replacement, ischemic stroke, myocardial infraction (heart attack), and pulmonary embolism can benefit from the usage of anticoagulants.

Different types of anticoagulants available in the market are Coumadin & indandiones (also called vitamin K antagonist), factor XA inhibitors, direct thrombin inhibitors, and heparin. Warfarin, sold under brand name Coumadin, is available in the U.S. only for human use. Indandiones are primarily used for pest control, especially mice and rabbit. Heparins, such as Lipo-Hepin, are injectable anticoagulants that activate antithrombin III. In the normal coagulation system, liquemin acts at multiple locations. Antithrombin III, a heparin cofactor, and heparin can prevent thrombosis by inactivating activated factor X and preventing the conversion of prothrombin to thrombin. By inhibiting the activation of the fibrin stabilizing factor, liquemin also prevents the formation of a stable fibrin clot.

Increase in number of knee and hip replacement surgeries raises the risk of developing deep vein thrombosis (DVT). Surgeries often result in prolonged immobility, which increases the risk of deep vein thrombosis (DVT) due to decreased blood flow in the body. According to the WHO 2016 report, the number of surgical procedures performed among the elderly population has increased. Rise in number of surgeries is expected to increase the likelihood of developing thromboembolic events after surgery, thereby boosting patient demand for anticoagulant treatment.

Anticoagulants Market Segmentation

Anticoagulants Market Key Players And Regions